Previous 10 | Next 10 |
2023-09-27 08:30:00 ET Despite a sizzling start to the year, growth stocks have suddenly found themselves on the outs with investors. Concerns about the global economy, persistently high interest rates, and stubborn levels of inflation have weighed heavily on pure-play growth stocks in the ...
BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki bring...
2023-09-23 08:45:00 ET In our modern age, the power of gene editing is undeniable. After years of foundational scientific research, it's now becoming possible to treat illnesses that were until very recently intractable. And (as is usually the case during periods of great innovation), there...
2023-09-22 15:00:17 ET More on the markets No Signs Of A Major Top Yet, Staying Long BofA strategists have changed their view of the S&P 500 target, up 4%. Quant stock news sentiment measure keeps improving - BofA Amazon, Disney, Boeing boosted in Wells F...
2023-09-19 08:00:00 ET Summary Caribou Biosciences shows promise with a 94% overall response rate in Phase 1 trials for CB-010, but faces a competitive CAR-T landscape. Financially robust with $292.5M liquid assets, but concerns arise from increasing R&D costs and declining li...
2023-08-08 17:19:01 ET Caribou Bioscience press release ( NASDAQ: CRBU ): Q2 GAAP EPS of -$0.48 beats by $0.01 . Revenue of $3.76M (-10.3% Y/Y) beats by $0.69M . For further details see: Caribou Bioscience GAAP EPS of -$0.48 beats by $0.01, revenue of $3....
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM -- -- CB-012 IND application submission fo...
2023-07-28 08:30:00 ET With shares of Caribou Biosciences (NASDAQ: CRBU) up by 51% in the past 30 days, there's more than one reason why you might want to consider a purchase for yourself. Between its recent release of some great early-stage data from its flagship program and its po...
2023-07-22 09:45:00 ET What does "off-the-shelf" mean to you in the context of advanced cancer treatments? If you said something along the lines of "a therapy that doesn't need lots of customization for each patient before being used," you're on the right track. For biotechs like Cari...
2023-07-21 10:00:00 ET Up by 32% in the past three months, Caribou Biosciences (NASDAQ: CRBU) is a pre-revenue biotech stock with explosive potential. Per some new data released on July 13, its candidate to treat lymphoma might be a massive winner in the making. But early stage ...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...